Organogenesis Holdings (ORGO) Long-Term Investments (2016 - 2026)

Organogenesis Holdings' (ORGO) quarterly Long-Term Investments came in at $2.4 million in Q1 2026, down 65.52% year-on-year from $7.0 million in Q1 2025, and little changed quarter-over-quarter from $2.4 million in Q4 2025.

Organogenesis Holdings (ORGO) Long-Term Investments (2016 - 2026) Analysis & Trends

Organogenesis Holdings' Long-Term Investments history runs 5 years deep, the most recent figure standing at $2.4 million for Q1 2026.

  • On a quarterly basis, Long-Term Investments fell 65.52% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 65.52% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, changed N/A from the prior year.
  • Long-Term Investments held at $2.4 million in Q1 2026 per ORGO's latest filing, from $2.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $7.0 million in Q1 2025 and bottomed at $2.4 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 56.09 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 1.32 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 702.35 Mn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 146.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Organogenesis Holdings 310.55 Mn 218.45 Mn 11.46 Mn 2.43 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.43 Mn
Dec 31, 2025 2.43 Mn
Sep 30, 2025 4.37 Mn
Jun 30, 2025 5.29 Mn
Mar 31, 2025 7.03 Mn
Sep 30, 2018 316.28 Mn
Jun 30, 2018 314.82 Mn
Mar 31, 2018 313.20 Mn
Dec 31, 2017 312.50 Mn
Sep 30, 2017 311.66 Mn
Jun 30, 2017 310.38 Mn
Mar 31, 2017 310.00 Mn
Dec 31, 2016 310.00 Mn